• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿帕替尼作为广泛期小细胞肺癌的维持治疗:一项单中心回顾性研究的结果。

Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.

机构信息

Department of Internal Medicine, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.

出版信息

J Cancer Res Clin Oncol. 2019 Jan;145(1):235-240. doi: 10.1007/s00432-018-2764-8. Epub 2018 Oct 6.

DOI:10.1007/s00432-018-2764-8
PMID:30293117
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6326003/
Abstract

PURPOSE

To evaluate the efficacy of maintenance apatinib after chemotherapy for extensive-stage (ED) small-cell lung cancer (SCLC).

PATIENTS AND METHODS

This was a retrospective analysis of 23 cases of extensive-stage SCLC admitted to the Affiliated Cancer Hospital of Zhengzhou University from January 2015 to December 2017. The patients without progression after induction chemotherapy received apatinib 250 mg per day until disease progression or unacceptable toxicity occurred. We analyzed the median progression-free survival (PFS), median overall survival (OS) and safety.

RESULTS

Of 23 enrolled patients, 1 was lost to follow-up. The median PFS from the time of maintenance therapy was 4.1 months (95% CI 3.63-4.57 months). The median PFS from the time of induction chemotherapy was 8.3 months (95% CI 7.20-9.40 months). The median OS from the time of maintenance therapy was 12.5 months (95% CI 5.51-19.49 months). The median OS from the time of induction chemotherapy was 17.0 months (95% CI 9.86-24.14 months). The most frequent treatment-related adverse events were hand-foot syndrome (43.5%, 10/23) and secondary hypertension (30.4%, 7/23), followed by fatigue, proteinuria, nausea, and oral mucositis (17.4%, 13.0%, 13.0%, and 8.7%, respectively). Hematologic toxicity included thrombocytopenia (30.4%), leucopenia (26.1%), and anemia (17.4%). The main grade 3 or 4 toxicities were hand-foot syndrome (8.7%, 2/23) and hypertension (4.3%, 1/23).

CONCLUSION

Maintenance apatinib was safe and achieved encouraging PFS and OS in extensive-stage SCLC.

摘要

目的

评估化疗后维持阿帕替尼治疗广泛期(ED)小细胞肺癌(SCLC)的疗效。

患者和方法

这是一项回顾性分析,纳入了 2015 年 1 月至 2017 年 12 月期间郑州大学附属肿瘤医院收治的 23 例广泛期 SCLC 患者。诱导化疗后无进展的患者接受阿帕替尼 250mg/天治疗,直至疾病进展或出现不可耐受的毒性。我们分析了中位无进展生存期(PFS)、中位总生存期(OS)和安全性。

结果

23 例纳入患者中,1 例失访。维持治疗开始后的中位 PFS 为 4.1 个月(95%CI 3.63-4.57 个月)。诱导化疗开始后的中位 PFS 为 8.3 个月(95%CI 7.20-9.40 个月)。维持治疗开始后的中位 OS 为 12.5 个月(95%CI 5.51-19.49 个月)。诱导化疗开始后的中位 OS 为 17.0 个月(95%CI 9.86-24.14 个月)。最常见的治疗相关不良反应为手足综合征(43.5%,23/53)和继发性高血压(30.4%,7/23),其次为乏力、蛋白尿、恶心和口腔黏膜炎(17.4%、13.0%、13.0%和 8.7%)。血液学毒性包括血小板减少症(30.4%)、白细胞减少症(26.1%)和贫血(17.4%)。主要的 3 级或 4 级毒性为手足综合征(8.7%,23/266)和高血压(4.3%,1/23)。

结论

维持阿帕替尼治疗广泛期 SCLC 安全有效,可获得令人鼓舞的 PFS 和 OS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a84b/11810430/94920ba5c37d/432_2018_2764_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a84b/11810430/5f699c3c6922/432_2018_2764_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a84b/11810430/94920ba5c37d/432_2018_2764_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a84b/11810430/5f699c3c6922/432_2018_2764_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a84b/11810430/94920ba5c37d/432_2018_2764_Fig2_HTML.jpg

相似文献

1
Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.阿帕替尼作为广泛期小细胞肺癌的维持治疗:一项单中心回顾性研究的结果。
J Cancer Res Clin Oncol. 2019 Jan;145(1):235-240. doi: 10.1007/s00432-018-2764-8. Epub 2018 Oct 6.
2
A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.一项阿帕替尼对比观察用于广泛期小细胞肺癌一线诱导化疗后维持治疗的随机 2 期临床试验。
Invest New Drugs. 2020 Feb;38(1):148-159. doi: 10.1007/s10637-019-00828-x. Epub 2019 Aug 9.
3
Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.阿帕替尼治疗化疗耐药广泛期小细胞肺癌:一项回顾性研究。
Cancer Chemother Pharmacol. 2019 Jun;83(6):1083-1090. doi: 10.1007/s00280-019-03823-4. Epub 2019 Apr 1.
4
Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.阿帕替尼治疗二线或三线化疗后广泛期小细胞肺癌患者的疗效:一项 II 期、单臂、多中心、前瞻性研究。
Br J Cancer. 2019 Oct;121(8):640-646. doi: 10.1038/s41416-019-0583-6. Epub 2019 Sep 16.
5
[Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].[依托泊苷+顺铂有效治疗及其不同疗程后续维持治疗在小细胞肺癌患者中的疗效及不良反应]
Zhonghua Zhong Liu Za Zhi. 2016 Jun 23;38(6):454-9. doi: 10.3760/cma.j.issn.0253-3766.2016.06.010.
6
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.顺铂、依托泊苷和贝伐单抗方案序贯口服依托泊苷和贝伐单抗维持治疗广泛期小细胞肺癌患者:单机构经验
Clin Lung Cancer. 2015 Nov;16(6):e229-34. doi: 10.1016/j.cllc.2015.05.005. Epub 2015 May 18.
7
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).预防性颅脑照射与舒尼替尼维持治疗对标准化疗后未经治疗的广泛期小细胞肺癌患者的积极相互作用:CALGB 30504(联盟)的二次分析
J Thorac Oncol. 2016 Mar;11(3):361-9. doi: 10.1016/j.jtho.2015.11.001. Epub 2015 Dec 24.
8
A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.阿帕替尼治疗经治晚期非鳞非小细胞肺癌的 II 期临床试验。
Clin Lung Cancer. 2018 Nov;19(6):e831-e842. doi: 10.1016/j.cllc.2018.06.002. Epub 2018 Jun 27.
9
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.阿帕替尼单药或联合治疗伴脑转移的非小细胞肺癌患者。
Oncol Res. 2020 Mar 27;28(2):127-133. doi: 10.3727/096504019X15707896762251. Epub 2019 Oct 14.
10
A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.阿帕替尼治疗广泛期小细胞肺癌患者二线及以上化疗失败后的前瞻性研究。
Oncologist. 2020 May;25(5):e833-e842. doi: 10.1634/theoncologist.2019-0391. Epub 2020 Apr 6.

引用本文的文献

1
Parotid metastases from primary lung cancer: Case series and systematic review of the features.原发性肺癌的腮腺转移:病例系列及特征的系统评价
Front Oncol. 2022 Aug 25;12:963094. doi: 10.3389/fonc.2022.963094. eCollection 2022.
2
Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.阿帕替尼作为广泛期小细胞肺癌一线标准化疗后维持治疗的疗效观察:一项Ⅱ期单臂临床试验。
Thorac Cancer. 2022 Feb;13(4):557-562. doi: 10.1111/1759-7714.14298. Epub 2022 Jan 14.
3
"Highly Exposed Chinese Herbal Medicine" Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study.

本文引用的文献

1
[Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].[依托泊苷+顺铂有效治疗及其不同疗程后续维持治疗在小细胞肺癌患者中的疗效及不良反应]
Zhonghua Zhong Liu Za Zhi. 2016 Jun 23;38(6):454-9. doi: 10.3760/cma.j.issn.0253-3766.2016.06.010.
2
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).未治疗的广泛期小细胞肺癌采用或不采用舒尼替尼维持治疗的化疗:一项随机、双盲、安慰剂对照的II期研究——CALGB 30504(联盟)
J Clin Oncol. 2015 May 20;33(15):1660-5. doi: 10.1200/JCO.2014.57.3105. Epub 2015 Mar 2.
3
“高暴露量中药”联合阿帕替尼作为广泛期小细胞肺癌一线或二线化疗后的维持治疗:一项单臂前瞻性研究
Dose Response. 2021 Nov 13;19(4):15593258211055016. doi: 10.1177/15593258211055016. eCollection 2021 Oct-Dec.
4
Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review.小细胞肺癌的真实世界治疗模式与结局:一项系统文献综述
J Thorac Dis. 2021 Jun;13(6):3692-3707. doi: 10.21037/jtd-20-3034.
5
Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report.阿帕替尼联合伊立替康治疗晚期小细胞食管癌:1例报告
Onco Targets Ther. 2021 Mar 18;14:1989-1995. doi: 10.2147/OTT.S295067. eCollection 2021.
6
Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment.阿帕替尼联合S-1用于晚期实体瘤姑息治疗的安全性。
Exp Ther Med. 2021 Jan;21(1):62. doi: 10.3892/etm.2020.9494. Epub 2020 Nov 19.
7
An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study.口服小分子VEGFR2抑制剂阿帕替尼治疗复发或难治性宫颈癌患者的真实世界研究
J Oncol. 2020 Jun 22;2020:3852373. doi: 10.1155/2020/3852373. eCollection 2020.
8
S-1 Maintenance Therapy in Extensive Stage Small-Cell Lung Cancer-A Randomized Clinical Study.广泛期小细胞肺癌 S-1 维持治疗的随机临床研究。
Cancer Control. 2020 Apr-Jun;27(2):1073274820932004. doi: 10.1177/1073274820932004.
9
Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review.低剂量阿帕替尼单药治疗晚期化疗难治性小细胞肺癌:病例系列报道及文献综述
J Int Med Res. 2020 Mar;48(3):300060519887276. doi: 10.1177/0300060519887276. Epub 2019 Dec 18.
10
Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.阿帕替尼治疗二线或三线化疗后广泛期小细胞肺癌患者的疗效:一项 II 期、单臂、多中心、前瞻性研究。
Br J Cancer. 2019 Oct;121(8):640-646. doi: 10.1038/s41416-019-0583-6. Epub 2019 Sep 16.
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.贝伐珠单抗联合化疗治疗未经治疗的广泛期小细胞肺癌的随机 II-III 期研究:IFCT-0802 试验结果†。
Ann Oncol. 2015 May;26(5):908-914. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.
4
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.索拉非尼联合化疗及作为广泛期小细胞肺癌维持治疗的II期试验。
Invest New Drugs. 2014 Apr;32(2):362-8. doi: 10.1007/s10637-013-0061-6. Epub 2014 Jan 15.
5
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.阿帕替尼治疗化疗耐药的晚期转移性胃腺癌:一项随机、安慰剂对照、平行对照、II 期临床试验结果。
J Clin Oncol. 2013 Sep 10;31(26):3219-25. doi: 10.1200/JCO.2013.48.8585. Epub 2013 Aug 5.
6
Small cell lung cancer.小细胞肺癌。
J Natl Compr Canc Netw. 2013 Jan 1;11(1):78-98. doi: 10.6004/jnccn.2013.0011.
7
Small-cell lung cancer.小细胞肺癌。
Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10.
8
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.新型选择性血管内皮生长因子受体-2 抑制剂 YN968D1 在晚期恶性肿瘤患者中的安全性和药代动力学。
BMC Cancer. 2010 Oct 5;10:529. doi: 10.1186/1471-2407-10-529.
9
Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.小细胞肺癌的维持或巩固治疗:系统评价和荟萃分析。
Lung Cancer. 2010 Nov;70(2):119-28. doi: 10.1016/j.lungcan.2010.02.001. Epub 2010 Feb 25.
10
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.广泛期小细胞肺癌的治疗:现状与展望。
Eur Respir J. 2010 Jan;35(1):202-15. doi: 10.1183/09031936.00105009.